What is the difference between a 503A pharmacy and a 503B outsourcing facility for semaglutide?

What is the difference between a 503A and 503B pharmacy for semaglutide?

A 503A pharmacy is a state-licensed pharmacy that compounds for an individual patient on a prescription, while a 503B outsourcing facility registers with FDA, is subject to FDA inspection and current good manufacturing practice requirements, and appears on FDA’s public list (100 facilities on Nov 6, 2026). For semaglutide, FDA stated on April 1, 2026 that outsourcing facilities may compound from the bulk drug only if it is on the 503B bulks list or the shortage list, neither of which applied, and that 503A pharmacies may not regularly compound essentially copies of an approved drug.

A plain description of two record types. It is not legal or medical advice.

What the public records show for each

Record503A pharmacy503B outsourcing facility
Who licenses or registers itState board of pharmacyFDA registration, plus state licenses where required
Public FDA list of all facilitiesNone100 registered facilities
Entries on FDA’s compounding actions list31774
Form 483s on that list243192
Warning letters on that list7237
GLP-1 warning letters in this index matched by name96

Counts come from FDA’s compounding inspections and actions page (current as of Oct 22, 2026), which covers actions from 2019 on, and this index. The counts reflect which facilities FDA inspected or acted on and posted; they are not a comparison of quality.

FDA’s statements, by date

Common questions

Can a 503B outsourcing facility make semaglutide now?

FDA stated on April 1, 2026 that outsourcing facilities may compound from bulk drug substances only if the substance is on the 503B bulks list or the drug is on the shortage list, and that semaglutide was on neither. On April 30, 2026 FDA proposed not adding semaglutide to the bulks list; no final determination appears in the Federal Register docket in this index.

Can a 503A pharmacy compound semaglutide?

FDA’s April 1, 2026 statement restates the 503A conditions: compounding for an individual patient on a prescription, and not regularly or in inordinate amounts making essentially copies of a commercially available drug. FDA gave semaglutide with vitamin B12 as an example that may be considered essentially a copy.

How do I check which kind a pharmacy is?

Look for it on FDA’s 503B list. If it is not there, it is not a registered outsourcing facility, and its license comes from a state board of pharmacy.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.